Candel Therapeutics Inc’s recent filing unveils that its Chief Scientific Officer Barone Francesca unloaded Company’s shares for reported $97783.0 on Jan 15 ’25. In the deal valued at $7.22 per share,13,534 shares were sold. As a result of this transaction, Barone Francesca now holds 110,673 shares worth roughly $0.97 million.
Then, Tyagarajan Seshu sold 14,322 shares, generating $103,476 in total proceeds. Upon selling the shares at $7.22, the Chief Technology Officer now owns 96,790 shares.
Before that, Schoch Charles sold 9,511 shares. Candel Therapeutics Inc shares valued at $68,717 were divested by the insider at a price of $7.22 per share. As a result of the transaction, Schoch Charles now holds 43,038 shares, worth roughly $0.38 million.
Citigroup initiated its Candel Therapeutics Inc [CADL] rating to a Buy in a research note published on February 20, 2025; the price target was $25. A number of analysts have revised their coverage, including Canaccord Genuity’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. BofA Securities began covering CADL with “Buy” recommendation on February 07, 2025. H.C. Wainwright started covering the stock on December 02, 2022. It rated CADL as “a Buy”.
Price Performance Review of CADL
On Friday, Candel Therapeutics Inc [NASDAQ:CADL] saw its stock jump 10.20% to $8.75. Over the last five days, the stock has gained 5.93%. Candel Therapeutics Inc shares have risen nearly 0.81% since the year began. Nevertheless, the stocks have risen 443.48% over the past one year. While a 52-week high of $14.60 was reached on 02/20/25, a 52-week low of $1.34 was recorded on 01/28/25. SMA at 50 days reached $8.26, while 200 days put it at $6.73.
Levels Of Support And Resistance For CADL Stock
The 24-hour chart illustrates a support level at 8.21, which if violated will result in even more drops to 7.67. On the upside, there is a resistance level at 9.04. A further resistance level may holdings at 9.33. The Relative Strength Index (RSI) on the 14-day chart is 52.73, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.01, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 66.67%. Stochastics %K at 21.05% indicates the stock is a holding.
How much short interest is there in Candel Therapeutics Inc?
A steep rise in short interest was recorded in Candel Therapeutics Inc stocks on 2025-02-28, growing by 0.69 million shares to a total of 3.34 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 2.64 million shares. There was a rise of 20.77%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 19, 2021 when BMO Capital Markets began covering the stock and recommended ‘”an Outperform”‘ rating along with a $18 price target.
